News Search Results
Mar 24, 2026, 09:03 ET Xtressé™ Announces FDA IND Acceptance for Xvie, The First & Only Extracellular Vesicle Injectable Therapy for Androgenetic Alopecia
application will be evaluated through the FDA clinical trial process and is not approved for use.References1American Academy of Dermatology 2024, accessed
More news about: Xtressé™
Mar 24, 2026, 07:30 ET Alphyn Completes Enrollment in Phase 2 Trial of Topical Therapy for Molluscum Contagiosum
with only one mechanism of action, directly addressing only one disease symptom.Alphyn will be exhibiting at Booth 2555 at the American Academy of Dermatology annual meeting March 27-29 in Denver. Please visit us to learn more about our platform and dermatology programs.ABOUT ALPHYN
More news about: Alphyn Biologics
Mar 23, 2026, 07:30 ET HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
lymphoma (CTCL) are being presented at the United States Cutaneous Lymphoma Consortium (USCLC) Workshop (March 26, 2026), which precedes the American Academy of Dermatology (AAD) Annual Meeting. Ellen Kim, MD, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department,
More news about: Soligenix
Mar 20, 2026, 10:00 ET Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting
Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata have been accepted for two oral presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place March 27-31, 2026, in Denver, CO.
More news about: Nektar Therapeutics
Mar 18, 2026, 07:49 ET FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
consensus on defining failure of topical therapy in psoriasis: Recommendations from the International Psoriasis Council. Journal of the American Academy of Dermatology, Volume 94, Issue 1, 372 – 375.7 Simpson E, Bissonnette R, Eichenfield LF, et al. The validated Investigator Global
More news about: Johnson & Johnson
Mar 12, 2026, 16:15 ET Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
period of the REZOLVE-AA study in patients with alopecia areata were accepted for a presentation in a late-breaking oral session at the American Academy of Dermatology (AAD) 2026 Annual Meeting to be held March 27-31, 2026, in Denver, CO.Topline data to be reported from the blinded 16-week treatment
More news about: Nektar Therapeutics
Feb 27, 2026, 08:11 ET Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review. Journal of the American Academy of Dermatology, 85(1), 162–175.
More news about: Eli Lilly and Company
Feb 24, 2026, 16:15 ET HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES
meaningful reductions in pain and itchingZero dose-limiting toxicities observed across the entire trial to dateAt the American Academy of Dermatology Annual Meeting, a case study demonstrated complete lesion and symptom resolution after just one week of twice-daily application in a metastatic
More news about: Hoth Therapeutics, Inc.
Feb 19, 2026, 08:14 ET SciBase's Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma
judgment," said Dr. Darrell Rigel, MD, Clinical Professor of Dermatology at the New York University (NYU), and Past President of the American Academy of Dermatology. "While visual assessment and dermoscopy have long been shown to improve melanoma detection rates, our published clinical research demonstrates
More news about: SciBase
Feb 18, 2026, 06:45 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry. Journal of the American Academy of Dermatology, Volume 86, Issue 1, 68 - 76.4 Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab
More news about: Eli Lilly and Company
Jan 22, 2026, 10:07 ET Ezderm Unveils Platform Evolution: Introduces 'Eve' AI Ecosystem and 'Compass' Clinical Interface
Debuting this March at the 2026 American Academy of Dermatology (AAD) Annual Meeting, Eve is a proprietary AI ecosystem fully embedded in the Ezderm EHR and Practice Management platform. From encounter
More news about: Ezderm, LLC
Jan 20, 2026, 07:00 ET Clinical Trial Demonstrates Accurate Non-Invasive Detection of In Vivo Biologic Activity in Melanomas by the Orlucent® Skin Fluorescent Imaging System
solutions for the non-invasive detection of melanoma activity, were published in the February edition of the peer-reviewed Journal of the American Academy of Dermatology (JAAD) International.
More news about: Orlucent, Inc.
Jan 07, 2026, 17:31 ET Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight
Therapeutics announced the presentation of two head-to-head preclinical studies of its oral psoriasis treatment candidate, SFA-002, at the American Academy of Dermatology Annual Meeting in Orlando, Florida.In March 2025, Boehringer Ingelheim presented new post-hoc exploratory analyses from
More news about: DelveInsight Business Research, LLP
Jan 06, 2026, 11:40 ET Joint statement from the American Academy of Dermatology Association and the New York State Society of Dermatology and Dermatologic Surgery on New York City Council medspa investigation
the AADAHeadquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. A sister organization to the Academy, the American Academy of Dermatology Association is the resource for government
More news about: American Academy of Dermatology Association
Jan 06, 2026, 08:48 ET Leaf & Mineral™ Helps With Dry Skin When Cleaning in Cold Weather
trickle-down effect that does more than amp up energy bills and make it hard to get to work in the morning. It could also dry out the skin. The American Academy of Dermatology
More news about: Leaf & Mineral
Dec 18, 2025, 02:00 ET New Data from SkylineDx Demonstrates Merlin CP-GEP Test's Superior Melanoma Risk Stratification
newly published analysis4 in Journal of American Academy of Dermatology about early-stage T1a melanoma showed that Merlin CP-GEP High-Risk reliably identifies patients with >10% risk of SLNB metastasis, suggesting
More news about: SkylineDx
Dec 15, 2025, 07:00 ET Laser by Aleya Expands Client Education and Personalized Care to Support Women's Skin Health at Every Stage
understand their treatment options beyond surface-level aesthetics.Industry ContextAccording to a 2023 report by the American Academy of Dermatology, conditions like PCOS and menopause can cause significant changes in hair growth and skin barrier stability, yet many women report receiving
More news about: Laser by Aleya
Dec 11, 2025, 11:09 ET American Academy of Dermatology Association Statement on FDA Proposal for New Sunscreen Ingredient
Statement from Susan C. Taylor, MD, FAAD, President, American Academy of DermatologyROSEMONT, Ill., Dec. 11, 2025 /PRNewswire/ -- The American Academy of Dermatology Association applauds the Food and Drug Administration
More news about: American Academy of Dermatology Association
Nov 25, 2025, 22:51 ET FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)
label update.The long-term results from the pivotal open-label study of UNLOXCYT in aCSCC were published in the Journal of the American Academy of Dermatology (JAAD), further validating the strength of the data.MUMBAI, India and PRINCETON, N.J.,
More news about: Sun Pharma
Nov 05, 2025, 10:44 ET Laser by Aleya Introduces Stress-Responsive Skin Consultation to Help Clients Manage Inflammation, Sensitivity, and Breakouts
control. Scientific Context According to the American Academy of Dermatology, chronic stress can disrupt the skin's immune response, delay healing, and contribute to conditions like acne, eczema, and psoriasis.
More news about: Laser by Aleya
Oct 29, 2025, 09:06 ET Top Cincinnati Dermatologist Dr. Kristine Zitelli Named 2026 Cincinnati Magazine Top Doctor for Dermatology
Medicine Award from the Department of Dermatology. She is board-certified by the American Board of Dermatology and is a Fellow of the American Academy of Dermatology (FAAD). In addition to her ten consecutive years as a Cincinnati Magazine Top Doctor (2017-2026), Dr. Zitelli was
More news about: Queen City Dermatology
Oct 28, 2025, 12:17 ET A Dermatologist's Guide to Skincare from Growing Up to Glowing Up
About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more
More news about: American Academy of Dermatology
Oct 24, 2025, 06:45 ET Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis
strong recommendation and high certainty of evidence that can be used with or without topicals, according to guidelines published by the American Academy of Dermatology (AAD),** which are used as a key consideration for dermatologists and managed care providers. Lilly continues to
More news about: Eli Lilly and Company
Oct 24, 2025, 06:45 ET Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
36-week results from the BRAVE-AA-PEDS trial previously presented at the 2025 American Academy of Dermatology (AAD) annual meeting in March. "For nearly half of the people with severe alopecia areata, the disease starts before
More news about: Eli Lilly and Company
Oct 14, 2025, 07:30 ET Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
Cutaneous Lymphoma Foundation and a member of the U.S. Cutaneous Lymphoma Consortium. She is an editorial reviewer for the Journal of the American Academy of Dermatology. Youn Kim, MD
More news about: Soligenix